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Masked hypertension is diagnosed if the office blood
pressure reading is not increased but the out-ofoffice-blood pressure reading by either home blood
pressure monitoring or by ambulatory blood pressure
monitoring is increased (1-3). Patients being treated for
hypertension who have a normal office blood pressure
reading but an increased out-of-office-blood pressure
reading by either home blood pressure monitoring or
by ambulatory blood pressure monitoring should be
diagnosed as having masked uncontrolled hypertension (1).
The European Society of Hypertension diagnosed an
increased office blood pressure if the blood pressure
was 140/90 mm Hg or higher and an increased outof-office-blood pressure if the home blood pressure
reading was 135/85 mmHg or higher, the daytime blood
pressure reading measured by ambulatory blood pressure
monitoring was 135/85 mmHg or higher, or the 24-hour
ambulatory blood pressure reading was 130/80 mmHg
or higher (1). On the basis of current data, I would diagnose
hypertension if the office systolic blood pressure was
130 mmHg or higher or if the office diastolic blood pressure
was 80 mmHg or higher (4,5).
Masked hypertension might be suspected in persons
with an increased office blood pressure at some time, in
young persons with normal or high normal office blood
pressure who have left ventricular hypertrophy, in persons
who have a family history of hypertension in both parents,
in diabetics, in persons with multiple cardiovascular risk
factors, and in obese individuals (1). Masked hypertension
is estimated to occur in 10% to 30% of persons (1). Masked
hypertension was diagnosed by ambulatory blood pressure
monitoring in 14% of persons and by home blood pressure
monitoring by 11% of persons (6). It may be reasonable
to screen for masked hypertension with ambulatory
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blood pressure monitoring or with home blood pressure
monitoring if the office systolic blood pressure is 120 to
129 mmHg or if the office diastolic blood pressure is 75 to
79 mmHg (6-10).
The prevalence of masked uncontrolled hypertension
in 14,840 persons with treated hypertension in a Spanish
registry was 31.1% (3). The prevalence of masked
uncontrolled hypertension was higher in men, in persons
with a borderline office blood pressure, and in smokers,
diabetics, and obese persons (3). Of 5,007 persons with
untreated hypertension, 8.1% had masked hypertension (6).
Of 1,451 persons in this study with treated hypertension,
16.0% had masked uncontrolled hypertension. At
8.3-year median follow-up, cardiovascular events in those
with untreated hypertension were increased 55% in persons
with masked hypertension and 2.13 times in persons with
sustained hypertension. Cardiovascular events in persons
with treated hypertension were increased 76% in persons
with masked hypertension and 40% in persons with
uncontrolled hypertension (6).
Of 332 persons, 22% had masked hypertension (7).
Left ventricular mass index, carotid maximal intimamedia thickness, and urinary albumin level were higher
in persons with masked hypertension than in persons
with controlled hypertension and similar to those with
sustained hypertension (7). A meta-analysis of seven studies
including 11,502 persons, mean age 63 years, showed at
8.0-year follow-up that compared to normotensive persons,
persons with masked hypertension had a 2.0 times increase
in first cardiovascular events, and persons with sustained
hypertension had a 2.28 times increase in first cardiovascular
events (8).
A meta-analysis of eight studies including 7,964 persons
showed that compared to normotensive persons, persons
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with masked hypertension had at follow-up a 2.09 times
increase in cardiovascular events, and persons with sustained
hypertension had a 2.59 times increase in cardiovascular
events (9). In 8,237 untreated persons, mean age 50.7 years,
in 12 population studies, the prevalence of masked
hypertension ranged from 9.7% to 19.6% (10). At followup, compared to normotensive persons, persons with
masked hypertension had a 1.76 to 2.03 times increase in
cardiovascular events (10).
Of 1,332 Japanese persons, 16.6% had masked
hypertension (11). At 10-year follow-up, compared to
normotensive persons, persons with masked hypertension
had a 1.88 times increased risk of cardiovascular disease
mortality, a 2.17 times increased risk of stroke, and a
2.13 times increase in risk of cardiovascular disease
mortality and stroke (11). Compared to normotensive
persons, persons with sustained hypertension had a
1.94 times increased risk of cardiovascular disease
mortality, a 2.83 times increased risk of stroke, and a
2.26 times increase in risk of cardiovascular disease
mortality and stroke (11). Of 3,027 persons, mean age
47 years (50% blacks), in the Dallas Heart Study, 17.8%
had masked hypertension (12). Persons with masked
hypertension had increased aortic pulsed wave velocity,
cystatin C, and urinary albumin-to creatinine ratio. At
9.0-year median follow-up, after adjusting for traditional
cardiovascular risk factors, compared with normotensive
persons with masked hypertension had a 2.03 times
increased risk of cardiovascular events, and persons with
sustained hypertension had a 3.12 times increased risk of
cardiovascular events (12).
In 972 blacks, mean age 60 years, in the Jackson Heart
Study, masked hypertension was present in 25.9% of
persons and in 34.4% of persons with a normal clinic blood
pressure (13). Male gender, smoking, diabetes mellitus,
and use of antihypertensive drugs were independent
determinants of masked hypertension. Common carotid
artery intima-media thickness, left ventricular mass index,
and the urinary albumin to creatinine excretion ratio were
higher in persons with masked hypertension than in persons
with normal blood pressure and similar in persons with
masked hypertension and with sustained hypertension (13).
Fewer modifiable cardiovascular risk factors measured
by the American Heart Association Life’s Simple 7 was
associated with a lower prevalence of masked hypertension
in the Jackson Heart Study (14). In 644 participants in the
Jackson Heart Study, the 10-year predicted atherosclerotic
cardiovascular disease (ASCVD) risk was increased by
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masked hypertension 1.36 times by the pooled cohort risk
equation if the ASCVD risk was 5% to 7.4%, 1.62 times if
the ASCVD risk was 7.5% to 9.9%, and 1.91 times if the
ASCVD risk was ≥10% (15).
Of 5,636 Canadian persons with hypertension treated in
a primary care setting, 19.6% and 36.8% of persons with
controlled office blood pressure had masked uncontrolled
hypertension (16). Diabetes mellitus, older age, male gender,
obesity, and higher office systolic blood pressure were
associated with masked uncontrolled hypertension (16).
Of 803 persons, mean age 60 years, with treated and
controlled office blood pressure, 32.1% had masked
uncontrolled hypertension (17). Masked uncontrolled
hypertension was due to increased nocturnal blood pressure
in 22.3% of persons and to poor daytime blood pressure
increase in 10.1% of persons. Masked uncontrolled
hypertension was associated with male gender, longer
duration of hypertension, obesity, smoking, and diabetes
mellitus (17). Using data from 9,316 persons in the National
Health and Nutrition Examination Survey 2005–2010, the
estimated prevalence of masked hypertension in the United
States was 12.3% of adults (18). Masked hypertension was
higher in older persons, men, diabetics, and those with
prehypertension (18).
In 813 participants, mean age 45 years, without treated
hypertension in the Masked Hypertension Study, 15.2%
had masked hypertension (19). Echocardiographic left
ventricular mass index was higher in persons with masked
hypertension and in persons with prehypertension (19). In
652 Swiss persons, mean age 48 years, masked hypertension
was present in 15.8% of persons (20). Masked hypertension
was associated with age (odds ratio =1.02), high-normal
office blood pressure (odds ratio =6.68), and with obesity
(odds ratio =3.63) (20). In 588 Chinese patients with nondialysis chronic kidney disease, mean age 43 years, 20.6%
of patients had masked hypertension (21). At 35-month
median follow-up, masked hypertension increased all-cause
mortality 8.88 times, renal events 3.70 times, and major
adverse cardiac and cerebrovascular events 8.66 times (21).
Nocturnal hypertension and non-dipping may be early
markers of masked hypertension (22). Twenty-four hour
ambulatory monitoring is the gold standard for diagnosing
masked hypertension. Almost one-third of treated patients
with masked hypertension have masked uncontrolled
hypertension (22). There are scarce data on how to treat
masked hypertension (23). One approach to treating masked
hypertension would be to treat 24-hour ambulatory blood
pressure (23). I would also aggressively treat modifiable
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risk factors for masked hypertension. Although I would
treat masked hypertension because of its association with
increased cardiovascular and cerebrovascular events and
mortality, we do not have clinical trial data demonstrating
that treating masked hypertension will reduce cardiovascular
and cerebrovascular events and mortality. Since masked
hypertension may be a prognostic marker of adverse
cardiovascular and cerebrovascular events and mortality,
clinical trials need to be performed to investigate whether
masked hypertension should be treated with antihypertensive
drug therapy.

Page 3 of 4

9.

10.

11.

Acknowledgements
None.

12.

Footnote
Conflicts of Interest: The author has no conflicts of interest to
declare.

13.

References
1.

2.
3.

4.

5.

6.

7.

8.

O'Brien E, Parati G, Stergiou G, et al. European Society
of Hypertension position paper on ambulatory blood
pressure monitoring. J Hypertens 2013;31:1731-68.
Pickering TG, Davidson K, Gerin W, et al. Masked
hypertension. Hypertension 2002;40:795-6.
Banegas JR, Ruilope LM, de la Sierra A, et al. High
prevalence of masked uncontrolled hypertension in people
with treated hypertension. Eur Heart J 2014;35:3304-12.
Wright JT Jr, Williamson JD, Whelton PK, et al. A
randomized trial of intensive versus standard bloodpressure control. N Engl J Med 2015;373:2103-16.
Schiffrin EL, Calhoun DA, Flack JM. Do we need a new
definition of hypertension after SPRINT? Am J Hypertens
2016;29:1127-9.
Stergiou GS, Asayama K, Thijs L, et al. Prognosis of
white-coat and masked hypertension. International
database of home blood pressure in relation to
cardiovascular outcome. Hypertension 2014;63:675-82.
Tomiyama M, Horio T, Yoshii M, et al. Masked
hypertension and target organ damage in treated
hypertensive patients. Am J Hypertens 2006;19:880-6.
Fagard RH, Cornelissen VA. Incidence of cardiovascular
events in white-coat, masked and sustained hypertension
versus true normotension: a meta-analysis. J Hypertens
2007;25:2193-8.

© Annals of Translational Medicine. All rights reserved.

14.

15.

16.

17.

18.

19.

20.

Pierdomenico SD, Cuccurullo F. Prognostic value of
white-coat and masked hypertension diagnosed by
ambulatory monitoring in initially untreated subjects: an
updated meta-analysis. Am J Hypertens 2011;24:52-8.
Asayama K, Thijs L, Li Y, et al. Setting thresholds to
varying blood pressure monitoring intervals differentially
affects risk estimates associated with white-coat and
masked hypertension in the poulation. Hypertension
2014;64:935-42.
Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of
“masked” hypertension and “white-coat” hypertension
detected by 24-h ambulatory blood pressure monitoring:
10-year follow-up from the Ohasama study. J Am Coll
Cardiol 2005;46:508-15.
Tientcheu D, Ayers C, Das SR, et al. Target organ
complications and cardiovascular events associated with
masked hypertension and white-coat hypertension.
Analysis from the Dallas Heart Study. J Am Coll Cardiol
2015;66:2159-69.
Diaz KM, Veerabhadrappa P, Brown MD, et al.
Prevalence, determinants, and clinical significance of
masked hypertension in a population-based sample
of African-Americans: the Jackson Heart Study. Am J
Hypertens 2015;28:900-8.
Bromfield SG, Shimbo D, Booth JN III, et al.
Cadiovascular risk factors and masked hypertension. The
Jackson Heart Study. Hypertension 2016;68:1475-82.
Ansley DE, Booth JN II, Abdalla M, et al. Predicted
atherosclerotic cardiovascular disease risk and masked
hypertension among blacks in the Jackson Heart Study.
Circ Cardiovasc Qual Outcomes 2017;10:e003421.
Andalib A, Akhtari S, Rigal R, et al. Determinants of
masked hypertension in hypertensive patients treated in a
primary care setting. Intern Med J 2012;42:260-6.
Naser N, Dzubur A, Durak A, et al. Blood pressure control
in hypertensive patients, cardiovascular risk profile and the
prevalence of masked uncontrolled hypertension (MUCH).
Med Arch 2016;70:274-9.
Wang YC, Shimbo D, Muntner P, et al. Prevalence of
masked hypertension among US adults with nonelevated
clinic blood pressure. Am J Epidemiol 2017;185:194-202.
Shimbo D, Newman JD, Schwartz JE. Masked
hypertension and prehypertension: diagnostic overlap and
interrelationships with left ventricular mass: the Masked
Hypertension Study. Am J Hypertens 2012;25:664-71.
Alwan H, Pruijm M, Ponte B, et al. Epidemiology of
masked and white-coat hypertension: the family-based
SKIPOGH Study. PLoS One 2014;9: e92522.

atm.amegroups.com

Ann Transl Med 2017;5(23):456

Aronow. Masked hypertension

Page 4 of 4

21. Wang C, Zhang J, Li Y, et al. Masked hypertension, rather
than white-coat hypertension, has a prognostic role in
patients with non-dialysis chronic kidney disease. Int J
Cardiol 2017;230:33-9.
22. Franklin SS, O'Brien E, Staessen JA. Masked hypertension:

understanding its complexity. Eur Heart J 2017;38:1112-8.
23. Peacock J, Diaz KM, Viera AJ, et al. Unmasking masked
hypertension: prevalence, clinical implications, diagnosis,
correlates and future directions. J Hum Hypertens
2014;28:521-8.

Cite this article as: Aronow WS. Masked hypertension. Ann
Transl Med 2017;5(23):456. doi: 10.21037/atm.2017.09.24

© Annals of Translational Medicine. All rights reserved.

atm.amegroups.com

Ann Transl Med 2017;5(23):456

